JP2008538775A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008538775A5 JP2008538775A5 JP2008508131A JP2008508131A JP2008538775A5 JP 2008538775 A5 JP2008538775 A5 JP 2008538775A5 JP 2008508131 A JP2008508131 A JP 2008508131A JP 2008508131 A JP2008508131 A JP 2008508131A JP 2008538775 A5 JP2008538775 A5 JP 2008538775A5
- Authority
- JP
- Japan
- Prior art keywords
- present
- formula
- protecting group
- reactions
- anxiety
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000006239 protecting group Chemical group 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 208000019901 Anxiety disease Diseases 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 208000011688 Generalised anxiety disease Diseases 0.000 description 2
- 102100038357 Metabotropic glutamate receptor 5 Human genes 0.000 description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 208000029364 generalized anxiety disease Diseases 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 208000028173 post-traumatic stress disease Diseases 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 238000003797 solvolysis reaction Methods 0.000 description 2
- 206010013654 Drug abuse Diseases 0.000 description 1
- 208000001914 Fragile X syndrome Diseases 0.000 description 1
- 101001032845 Homo sapiens Metabotropic glutamate receptor 5 Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- -1 carboxy, hydroxy, amino Chemical group 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000006266 etherification reaction Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical class OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- 238000006303 photolysis reaction Methods 0.000 description 1
- 230000015843 photosynthesis, light reaction Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical class OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0508318.3A GB0508318D0 (en) | 2005-04-25 | 2005-04-25 | Organic compounds |
| PCT/EP2006/003764 WO2006114260A1 (en) | 2005-04-25 | 2006-04-24 | Phenylacetylene derivatives having mglur5 receptor affinity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008538775A JP2008538775A (ja) | 2008-11-06 |
| JP2008538775A5 true JP2008538775A5 (https=) | 2009-06-18 |
Family
ID=34640066
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008508131A Pending JP2008538775A (ja) | 2005-04-25 | 2006-04-24 | ｍＧｌｕＲ５受容体親和性を有するフェニルアセチレン誘導体 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20080188490A1 (https=) |
| EP (1) | EP1877364B1 (https=) |
| JP (1) | JP2008538775A (https=) |
| KR (1) | KR20070122224A (https=) |
| CN (1) | CN101163662A (https=) |
| AT (1) | ATE427927T1 (https=) |
| AU (1) | AU2006239545A1 (https=) |
| BR (1) | BRPI0610337A2 (https=) |
| CA (1) | CA2605262A1 (https=) |
| DE (1) | DE602006006170D1 (https=) |
| ES (1) | ES2323288T3 (https=) |
| GB (1) | GB0508318D0 (https=) |
| MX (1) | MX2007013238A (https=) |
| PL (1) | PL1877364T3 (https=) |
| PT (1) | PT1877364E (https=) |
| RU (1) | RU2007143507A (https=) |
| WO (1) | WO2006114260A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100381083C (zh) | 2003-04-29 | 2008-04-16 | 韩力 | 一种非可燃性电子喷雾香烟 |
| CN2719043Y (zh) * | 2004-04-14 | 2005-08-24 | 韩力 | 雾化电子烟 |
| GB0503646D0 (en) * | 2005-02-22 | 2005-03-30 | Novartis Ag | Organic compounds |
| GB0508314D0 (en) * | 2005-04-25 | 2005-06-01 | Novartis Ag | Organic compounds |
| GB0508319D0 (en) * | 2005-04-25 | 2005-06-01 | Novartis Ag | Organic compounds |
| CN201067079Y (zh) * | 2006-05-16 | 2008-06-04 | 韩力 | 仿真气溶胶吸入器 |
| KR101572280B1 (ko) * | 2007-10-12 | 2015-11-26 | 노파르티스 아게 | 파킨슨병의 치료를 위한 대사성 글루타메이트 수용체 조절제 |
| WO2009047303A2 (en) * | 2007-10-12 | 2009-04-16 | Novartis Ag | Metabotropic glutamate receptor modulators for the treatment of pervasive developmental disorder |
| JPWO2009130900A1 (ja) * | 2008-04-24 | 2011-08-11 | 日本曹達株式会社 | オキシム誘導体、中間体化合物および植物病害防除剤 |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| US20120142932A1 (en) | 2009-09-08 | 2012-06-07 | Koji Kawamura | Method for manufacturing 4-(5-methylpyridin-2-ylamino)piperidine-1-carboxylic acid derivative |
| WO2011092290A1 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists |
| AR080056A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de ciclohexil-amida como antagonistas de los receptores de crf |
| EP2531490B1 (en) | 2010-02-02 | 2014-10-15 | Novartis AG | Cyclohexyl amide derivatives as crf receptor antagonists |
| EA023020B1 (ru) * | 2010-07-09 | 2016-04-29 | Рекордати Айерленд Лимитед | Спирогетероциклические соединения и их применение в качестве антагонистов mglu5 |
| JP2014527981A (ja) | 2011-09-23 | 2014-10-23 | アドヴィナス・セラピューティックス・リミテッド | アミド化合物、組成物およびその用途 |
| WO2014124560A1 (en) * | 2013-02-18 | 2014-08-21 | Hua Medicine (Shanghai) Ltd. | Mglur regulators |
| KR20180067010A (ko) | 2016-12-12 | 2018-06-20 | 김선권 | 금속판에 다양한 곡면을 성형하는 방법 |
| KR20180067030A (ko) | 2016-12-12 | 2018-06-20 | 김성갑 | 금속판에 다양한 곡면을 성형하는 방법 |
| WO2020032080A1 (ja) * | 2018-08-07 | 2020-02-13 | 学校法人慶應義塾 | 化合物、化合物の塩、神経機能調節物質、神経機能調節物質の評価方法、化合物の製造方法、及び化合物の塩の製造方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3991064A (en) * | 1975-01-17 | 1976-11-09 | Warner-Lambert Company | Benzonaphthyridines |
| CA2156836A1 (en) * | 1993-03-18 | 1994-09-29 | Janusz Jozef Kulagowski | Benzimidazole derivatives |
| US5576336A (en) * | 1993-03-18 | 1996-11-19 | Merck Sharp & Dohme Limited | Indole derivatives as dopamine D4 antagonists |
| US5521297A (en) * | 1993-06-04 | 1996-05-28 | Salk Institute Biotechnology/Industrial Associates | Nucleic acids encoding human metabotropic glutamate receptors |
| WO1995029911A1 (en) * | 1994-04-28 | 1995-11-09 | Merck Sharp & Dohme Limited | Benzofuran derivatives as d4 receptor antagonists |
| US5830901A (en) * | 1994-08-10 | 1998-11-03 | Merch Sharp & Dohme Ltd | Tetrahydropyridinylmethyl derivatives of pyrrolo 2,3-B!pyridine |
| US5688798A (en) * | 1995-10-10 | 1997-11-18 | Hoffmann-La Roche Inc. | Pyrimidine compounds |
| AUPR201600A0 (en) * | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
| GB0128996D0 (en) * | 2001-12-04 | 2002-01-23 | Novartis Ag | Organic compounds |
| US6806279B2 (en) * | 2001-12-17 | 2004-10-19 | Sunesis Pharmaceuticals, Inc. | Small-molecule inhibitors of interleukin-2 |
| US6995144B2 (en) * | 2002-03-14 | 2006-02-07 | Eisai Co., Ltd. | Nitrogen containing heterocyclic compounds and medicines containing the same |
| GB0503646D0 (en) * | 2005-02-22 | 2005-03-30 | Novartis Ag | Organic compounds |
| GB0508319D0 (en) * | 2005-04-25 | 2005-06-01 | Novartis Ag | Organic compounds |
| GB0508314D0 (en) * | 2005-04-25 | 2005-06-01 | Novartis Ag | Organic compounds |
-
2005
- 2005-04-25 GB GBGB0508318.3A patent/GB0508318D0/en not_active Ceased
-
2006
- 2006-04-24 ES ES06724538T patent/ES2323288T3/es not_active Expired - Lifetime
- 2006-04-24 AT AT06724538T patent/ATE427927T1/de not_active IP Right Cessation
- 2006-04-24 KR KR1020077024419A patent/KR20070122224A/ko not_active Withdrawn
- 2006-04-24 WO PCT/EP2006/003764 patent/WO2006114260A1/en not_active Ceased
- 2006-04-24 MX MX2007013238A patent/MX2007013238A/es not_active Application Discontinuation
- 2006-04-24 JP JP2008508131A patent/JP2008538775A/ja active Pending
- 2006-04-24 CA CA002605262A patent/CA2605262A1/en not_active Abandoned
- 2006-04-24 DE DE602006006170T patent/DE602006006170D1/de not_active Expired - Lifetime
- 2006-04-24 AU AU2006239545A patent/AU2006239545A1/en not_active Abandoned
- 2006-04-24 EP EP06724538A patent/EP1877364B1/en not_active Expired - Lifetime
- 2006-04-24 PT PT06724538T patent/PT1877364E/pt unknown
- 2006-04-24 RU RU2007143507/04A patent/RU2007143507A/ru not_active Application Discontinuation
- 2006-04-24 PL PL06724538T patent/PL1877364T3/pl unknown
- 2006-04-24 CN CNA2006800136880A patent/CN101163662A/zh active Pending
- 2006-04-24 US US11/912,624 patent/US20080188490A1/en not_active Abandoned
- 2006-04-24 BR BRPI0610337-5A patent/BRPI0610337A2/pt not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008538775A5 (https=) | ||
| JP2008538779A5 (https=) | ||
| EP2057153B1 (en) | (3-aryl-piperazin-1-yl) derivatives of 6,7-dialkoxyquinazoline, 6,7- dialkoxyphtalazine and 6,7-dialkoxyisoquinoline | |
| EP3872077A1 (en) | Heterocyclic amide for inhibiting rip1 kinase and uses thereof | |
| Glossop et al. | Inhalation by design: novel ultra-long-acting β2-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup | |
| CN101616894A (zh) | 作为丝氨酸蛋白酶抑制剂的式(ⅰ)化合物 | |
| JP4381804B2 (ja) | ２，６，９−置換プリン誘導体及び増殖性疾患の治療におけるその使用 | |
| CN103570725A (zh) | 哌嗪并三唑类化合物及其制备方法和用途 | |
| JP2020503288A (ja) | 選択的ヤヌスキナーゼ阻害剤としてのアミノピラゾール類 | |
| Frederickson et al. | Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator | |
| JP2015107945A (ja) | 神経新生に関する化合物及び医薬組成物 | |
| TW200740779A (en) | Intermediate compound for synthesizing pharmaceutical agent and production method thereof | |
| JP2018515614A5 (https=) | ||
| CN106831780A (zh) | 具有cdk4/6和hdac抑制活性的新型杂环衍生物 | |
| JP2014511865A (ja) | 水溶液中で多量化できるシリル単量体、およびその使用法 | |
| CN102076663A (zh) | 作为趋化因子受体活性的调节剂的哌啶衍生物 | |
| JP2013507377A (ja) | ケモカイン受容体活性の調節薬としてのピペリジニル誘導体のプロドラッグ | |
| JPH11189586A (ja) | キノリン誘導体、イソキノリン誘導体、およびシンノリン誘導体、並びに抗炎症剤および抗アレルギー剤 | |
| JP6542236B2 (ja) | 有機化合物 | |
| WO2015076359A1 (ja) | プロテアソーム阻害性化合物 | |
| US11639325B2 (en) | Compositions of polyhydroxylated benzophenones and methods of treatment of neurodegenerative disorders | |
| ATE431855T1 (de) | Menschliches autismus-suszeptibilitätsgen und verwendungen davon | |
| Hu et al. | Identification, synthesis, and strategy for minimization of potential impurities in the preclinical anti-HBV drug Y101 | |
| IL185868A0 (en) | Human autism susceptibility gene encoding a transmembrane protein and uses thereof | |
| Kang et al. | A highly stereoselective and efficient synthesis of enantiomerically pure sitagliptin |